Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser

Basit Öğe Kaydı
dc.contributor.authorKalyoncu, OA
dc.contributor.authorTan, D
dc.contributor.authorMirsal, H
dc.contributor.authorPektas, O
dc.contributor.authorBeyazyurek, M
dc.date.accessioned2024-07-12T21:51:21Z
dc.date.available2024-07-12T21:51:21Z
dc.date.issued2005en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractInfectious diseases, especially hepatitis C, are prevalent among drug abusers. Interferon-alpha (IFN-alpha) is the pharmacological treatment of choice for this condition. Patients being treated with IFN-alpha can be expected to experience such psychiatric side-effects as development of depression, mania, irritability, changes in personality, hallucinations or delirium. In addition, certain patients are considered to be at greater risk of developing neuropsychiatric side-effects. Individuals meeting the following criteria are particularly vulnerable: over 40 years of age; having central nervous system abnormalities; a previous neurological or psychiatric history; a past familial psychiatric history; use of narcotics or having alcohol or substance use disorders; being HIV-positive; coadministration of other cytokines; receiving high doses of IFN-alpha (> 6 million units). We report the case of a 29-year-old patient with chronic non-active hepatitis C, a previous psychiatric history of polydrug abuse (cannabis, heroin and illegal use of the psychotropic drug biperiden) and anxiety disorder. Two weeks after the initiation of IFN-alpha treatment, he developed fatigue, sleeplessness and persecutory delusions. The patient responded partially to the discontinuation of the IFN-alpha treatment. Due to the presence of three risk factors in this patient, he was considered to belong to the group of patients being 'at high risk' of developing neuropsychiatric side-effects. This is the first case report of major depressive disorder with psychotic features in such a 'high-risk patient' This case report may prompt other research by showing the importance of the close monitoring, and the prevention of the progression of IFN-alpha-related psychiatric disorders in 'at high-risk patient'.en_US
dc.identifier.doi10.1177/0269881105048905
dc.identifier.endpage105en_US
dc.identifier.issn0269-8811
dc.identifier.issn1461-7285
dc.identifier.issue1en_US
dc.identifier.pmid15671136en_US
dc.identifier.scopus2-s2.0-12444262184en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage102en_US
dc.identifier.urihttps://dx.doi.org/10.1177/0269881105048905
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8259
dc.identifier.volume19en_US
dc.identifier.wosWOS:000226560800015en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSAGE PUBLICATIONS LTDen_US
dc.relation.ispartofJOURNAL OF PSYCHOPHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY02022
dc.subjectdepressionen_US
dc.subjectdrug abuseen_US
dc.subjecthepatitis Cen_US
dc.subjectinterferon-alphaen_US
dc.titleMajor depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuseren_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu